Sanchez-Russo L, Rajasekaran A, Bin S, Faith J, Cravedi P. The gut and kidney crosstalk in immunoglobulin a nephropathy. Kidney. 2022;3:1630–9.

Article  Google Scholar 

Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn’s disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836–41.

Article  CAS  PubMed  Google Scholar 

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH, NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103:391–402.

Article  CAS  PubMed  Google Scholar 

Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd Trial Investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859–70.

Article  CAS  PubMed  Google Scholar 

Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.

Article  CAS  PubMed  Google Scholar 

Nakayama T, Kaneko H, Okada A, Suzuki Y, Fujiu K, Takeda N, Morita H, Takeda N, Fukui A, Yokoo T, Yasunaga H, Nangaku M, Hayashi K. Association of inflammatory bowel disease with incident IgA nephropathy. Clin J Am Soc Nephrol. 2024;19:704–11.

Article  PubMed  Google Scholar 

Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory bowel disease is more common in patients with iga nephropathy and predicts progression of ESKD: a swedish population-based cohort study. J Am Soc Nephrol. 2021;32:411–23.

Article  CAS  PubMed  Google Scholar 

Shi D, Zhong Z, Wang M, Cai L, Fu D, Peng Y, Guo L, Mao H, Yu X, Li M. Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population. J Hum Genet. 2020;65:241–9.

Article  CAS  PubMed  Google Scholar 

Larson C, Munir N, Rao P, Farkash E, Kathuria P, Romain D, Berinstein J. Crohn’s disease associated with IgA nephropathy effectively treated with the interleukin-23 inhibitor risankizumab. ACG Case Rep J. 2024;11: e01437.

Article  PubMed  PubMed Central  Google Scholar 

Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K. Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy. Clin J Gastroenterol. 2009;2:380–3.

Article  PubMed  Google Scholar 

Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, Abe K, Taguma Y. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.

Article  CAS  PubMed  Google Scholar 

Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y, Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawamura T, Hirano K, Koike K, Nishikawa M, Shimizu A, Joh K, Katafuchi R, Hashiguchi A, Matsuzaki K, Maruyama S, Tsuboi N, Narita I, Yano Y, Yokoo T, Suzuki Y. Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy. Sci Rep. 2023;13:18455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;6:CD000296.

Google Scholar 

Shimizu A, Tsuboi N, Haruhara K, Shirai I, Ogawa K, Miura A, Oshiro K, Ueda H, Yokote S, Okabe M, Sasaki T, Ikeda M, Yokoo T. Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-α antibody drugs for Crohn’s disease: three case reports and literature review. CEN Case Rep. 2024;13(4):249–57.

Article  PubMed  Google Scholar 

Rasmussen C, Abitbol V, El Karoui K, Bourrier A, Paule R, Vuitton L, Maurier F, Laharie D, Fuméry M, Agard C, Collins M, Nancey S, Rafat C, Kervegant AG, Queyrel-Moranne V, Moulis G, Pigneur B, Régent A, Gay C, Morbieu C, Durel CA, Ducloux D, Aubin F, Voicu M, Joher N, Szwebel T, Martinez-Vinson C, Koch S, Guillevin L, Peyrin-Biroulet L, Terrier B. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockers. Rheumatology (Oxford). 2022;61(5):1957–65.

Article  CAS  PubMed  Google Scholar